[{"AccountsPayableCurrent_0_Q2_USD":2650000.0,"SellingAndMarketingExpense_2_Q2_USD":13283000.0,"SellingAndMarketingExpense_1_Q2_USD":6153000.0,"ProceedsFromStockOptionsExercised_2_Q2_USD":506000.0,"DepreciationDepletionAndAmortization_2_Q2_USD":1441000.0,"AdditionalPaidInCapitalCommonStock_0_Q2_USD":447033000.0,"IncreaseDecreaseInAccruedLiabilities_2_Q2_USD":-1866000.0,"StockIssuedDuringPeriodValueNewIssues_1_Q2_USD":50017000.0,"NonoperatingIncomeExpense_2_Q2_USD":-23582000.0,"NonoperatingIncomeExpense_1_Q2_USD":-18684000.0,"EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_0_Q2_USD":13121000.0,"CostOfGoodsAndServicesSold_2_Q2_USD":953000.0,"CapitalExpendituresIncurredButNotYetPaid_2_Q2_USD":63000.0,"InventoryWorkInProcess_0_Q2_USD":106000.0,"InventoryRawMaterials_0_Q2_USD":235000.0,"InventoryFinishedGoods_0_Q2_USD":726000.0,"IncreaseDecreaseInInventories_2_Q2_USD":113000.0,"StockIssuedDuringPeriodValueStockOptionsExercised_1_Q2_USD":378000.0,"ShareBasedCompensation_2_Q2_USD":3491000.0,"ResearchAndDevelopmentExpense_2_Q2_USD":14119000.0,"ResearchAndDevelopmentExpense_1_Q2_USD":8021000.0,"CostOfGoodsAndServicesSold_1_Q2_USD":134000.0,"PreferredStockValue_0_Q2_USD":null,"LongTermNotesPayable_0_Q2_USD":20970000.0,"AllocatedShareBasedCompensationExpense_1_Q2_USD":1826000.0,"RevenueFromContractWithCustomerExcludingAssessedTax_1_Q2_USD":1569000.0,"RevenueFromContractWithCustomerExcludingAssessedTax_2_Q2_USD":4178000.0,"RestrictedCashAndCashEquivalentsNoncurrent_0_Q2_USD":1764000.0,"ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans_2_Q2_USD":350000.0,"OperatingLeaseRightOfUseAsset_0_Q2_USD":6269000.0,"OperatingLeaseLiabilityNoncurrent_0_Q2_USD":8256000.0,"OperatingLeaseLiabilityCurrent_0_Q2_USD":1238000.0,"InvestmentIncomeNet_2_Q2_USD":156000.0,"InvestmentIncomeNet_1_Q2_USD":17000.0,"CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0_Q2_USD":86058000.0,"IncomeTaxExaminationPenaltiesAndInterestAccrued_0_Q2_USD":0.0,"DerivativeGainLossOnDerivativeNet_1_Q2_USD":-17007000.0,"CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_2_Q2_USD":29857000.0,"AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_1_Q2_USD":1826000.0,"DerivativeLiabilitiesNoncurrent_0_Q2_USD":32535000.0,"AmortizationOfFinancingCosts_2_Q2_USD":2156000.0,"IncreaseDecreaseInDerivativeLiabilities_2_Q2_USD":-20411000.0,"DerivativeLiabilities_0_Q2_USD":32535000.0,"ConvertibleDebtNoncurrent_0_Q2_USD":26352000.0,"AllocatedShareBasedCompensationExpense_2_Q2_USD":3491000.0,"DerivativeGainLossOnDerivativeNet_2_Q2_USD":-20411000.0,"PreferredStockSharesOutstanding_0_Q2_shares":0.0,"PreferredStockSharesIssued_0_Q2_shares":0.0,"PreferredStockSharesAuthorized_0_Q2_shares":5000000.0,"LiabilitiesAndStockholdersEquity_0_Q2_USD":107260000.0,"Liabilities_0_Q2_USD":101916000.0,"InventoryNet_0_Q2_USD":1067000.0,"IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_2_Q2_USD":-173000.0,"IncreaseDecreaseInAccountsReceivable_2_Q2_USD":326000.0,"IncreaseDecreaseInAccountsPayable_2_Q2_USD":-786000.0,"GeneralAndAdministrativeExpense_2_Q2_USD":10321000.0,"GeneralAndAdministrativeExpense_1_Q2_USD":5145000.0,"EarningsPerShareBasicAndDiluted_2_Q2_USD":-1.06,"LiabilitiesCurrent_0_Q2_USD":13803000.0,"EarningsPerShareBasicAndDiluted_1_Q2_USD":-0.64,"CostsAndExpenses_1_Q2_USD":19453000.0,"CommonStockValue_0_Q2_USD":6000.0,"CommonStockSharesOutstanding_0_Q2_shares":62953793.0,"CommonStockSharesIssued_0_Q2_shares":62953793.0,"CashAndCashEquivalentsAtCarryingValue_0_Q2_USD":84294000.0,"AssetsCurrent_0_Q2_USD":90293000.0,"Assets_0_Q2_USD":107260000.0,"AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_2_Q2_shares":9289112.0,"AccountsReceivableNetCurrent_0_Q2_USD":2874000.0,"CostsAndExpenses_2_Q2_USD":38676000.0,"NetCashProvidedByUsedInFinancingActivities_2_Q2_USD":63881000.0,"NetCashProvidedByUsedInInvestingActivities_2_Q2_USD":-374000.0,"NetCashProvidedByUsedInOperatingActivities_2_Q2_USD":-33650000.0,"PreferredStockParOrStatedValuePerShare_0_Q2_USD":0.0001,"OperatingIncomeLoss_2_Q2_USD":-34498000.0,"OperatingIncomeLoss_1_Q2_USD":-17884000.0,"NotesPayableCurrent_0_Q2_USD":4146000.0,"InterestExpense_2_Q2_USD":3327000.0,"InterestExpense_1_Q2_USD":1694000.0,"CommonStockSharesAuthorized_0_Q2_shares":100000000.0,"CommonStockParOrStatedValuePerShare_0_Q2_USD":0.0001,"CommitmentsAndContingencies_0_Q2_USD":null,"AccruedLiabilitiesCurrent_0_Q2_USD":5769000.0,"WeightedAverageNumberOfShareOutstandingBasicAndDiluted_1_Q2_shares":57368292.0,"WeightedAverageNumberOfShareOutstandingBasicAndDiluted_2_Q2_shares":54634572.0,"StockholdersEquity_0_Q2_USD":5344000.0,"RetainedEarningsAccumulatedDeficit_0_Q2_USD":-441695000.0,"PropertyPlantAndEquipmentNet_0_Q2_USD":8934000.0,"ProfitLoss_2_Q2_USD":-58080000.0,"ProceedsFromIssuanceOfCommonStock_2_Q2_USD":63025000.0,"PrepaidExpenseAndOtherAssetsCurrent_0_Q2_USD":2058000.0,"PaymentsToAcquirePropertyPlantAndEquipment_2_Q2_USD":374000.0,"NetIncomeLoss_2_Q2_USD":-58080000.0,"NetIncomeLoss_1_Q2_USD":-36568000.0,"StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_1_Q2_USD":350000.0,"UnrecognizedTaxBenefits_0_Q2_USD":0.0,"Ticker":"OCUL","CIK":"1393434","name":"OCULAR THERAPEUTIX, INC","OfficialName":"Ocular Therapeutix Inc. Common Stock","form":"10-Q","period":"20200630","fy":"2020.0","fp":"Q2","qtrs":"0","uom":"USD","footnote":"nan","Market Cap":"305481557.0","Country":"United States","Sector":"Health Care","Industry":"Biotechnology: Pharmaceutical Preparations","Market":"NASDAQ","SP500":"nan","filed":"20200807"}]